Atlantic Edge Private Wealth Management LLC Lowers Stock Position in Merck & Co., Inc. $MRK

Atlantic Edge Private Wealth Management LLC lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,896 shares of the company’s stock after selling 970 shares during the quarter. Atlantic Edge Private Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $942,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Little House Capital LLC boosted its stake in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after acquiring an additional 308 shares in the last quarter. Semus Wealth Partners LLC boosted its stake in shares of Merck & Co., Inc. by 8.2% during the 1st quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock worth $452,000 after acquiring an additional 382 shares in the last quarter. Longfellow Investment Management Co. LLC boosted its stake in shares of Merck & Co., Inc. by 20.4% during the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after acquiring an additional 3,282 shares in the last quarter. Quilter Plc boosted its stake in shares of Merck & Co., Inc. by 5.6% during the 1st quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock worth $105,988,000 after acquiring an additional 62,933 shares in the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in shares of Merck & Co., Inc. by 9.8% during the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after acquiring an additional 79,529 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 1.8%

Shares of MRK opened at $86.30 on Tuesday. The stock has a fifty day moving average of $84.03 and a two-hundred day moving average of $81.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The company has a market capitalization of $215.56 billion, a PE ratio of 13.30, a price-to-earnings-growth ratio of 0.93 and a beta of 0.37. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $109.17.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.10. The company had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. Morgan Stanley reduced their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their target price for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Finally, Wells Fargo & Company reduced their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.